Søgeord (pseudomonas) valgt.
12 emner vises.
1
Communicable disease threats report, 21-27 May 2023, week 21
ECDC
ECDC COVID-19 updates, 27.05.2023
Tilføjet 27.05.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 21-27 May 2023 May 2023 and includes updates on COVID-19, influenza, Marburg virus disease, poliomyelitis, extensively drug-resistant Pseudomonas aeruginosa, and suspected fungal meningitis.
Læs mere
2
Communicable disease threats report, 21-27 May 2023, week 21
ECDC
ECDC Communicable Disease Threats Report, 26.05.2023
Tilføjet 26.05.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 21-27 May 2023 May 2023 and includes updates on COVID-19, influenza, Marburg virus disease, poliomyelitis, extensively drug-resistant Pseudomonas aeruginosa, and suspected fungal meningitis.
Læs mere
3
Clinical epidemiology and case fatality due to antimicrobial resistance in Germany: a systematic review and meta-analysis, 1 January 2010 to 31 December 2021
Maria Rödenbeck, Olaniyi Ayobami, Tim Eckmanns, Mathias W Pletz, Jutta Bleidorn and Robby Markwart
Eurosurveillance latest updates, 19.05.2023
Tilføjet 19.05.2023
BackgroundAntimicrobial resistance (AMR) is of public health concern worldwide. AimWe aimed to summarise the German AMR situation for clinicians and microbiologists. MethodsWe conducted a systematic review and meta-analysis of 60 published studies and data from the German Antibiotic-Resistance-Surveillance (ARS). Primary outcomes were AMR proportions in bacterial isolates from infected patients in Germany (2016–2021) and the case fatality rates (2010–2021). Random and fixed (common) effect models were used to calculate pooled proportions and pooled case fatality odds ratios, respectively. ResultsThe pooled proportion of meticillin resistance in Staphylococcus aureus infections (MRSA) was 7.9% with a declining trend between 2014 and 2020 (odds ratio (OR) = 0.89; 95% CI: 0.886–0.891; p
Læs mere
4
Communicable disease threats report 19 - 25 March, Week 12
ECDC
ECDC Communicable Disease Threats Report, 11.04.2023
Tilføjet 11.04.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19-25 March 2023 and includes updates on Marburg virus disease, iatrogenic botulism, COVID-19, Influenza, Group A streptococcal infection, cholera, poliomyelitis, measles, and extensively drug-resistant Pseudomonas aeruginosa.
Læs mere
5
PRO/EDR> Pseudomonas aeruginosa - USA (05): India-made/XDR/contam eye drops, RFI
ProMED, 6.04.2023
Tilføjet 6.04.2023
P. aeruginosa -- United StatesFederal inspectors found dozens of issues at an eye drops manufacturer now linked to a fatal outbreak of drug-resistant bacteria, inspection records released by the Food and Drug Administration show, ranging from dirty equipment and clothing to missing safeguards and procedures.The FDA's findings were detailed in citations issued to Indian manufacturer Global Pharma Healthcare Pvt Ltd after an inspection from 20 Feb through 2 Mar 2023. This appears to have been the company's 1st visit from
Læs mere
6
Communicable disease threats report 19 - 25 March, Week 12
ECDC COVID-19 updates, 25.03.2023
Tilføjet 25.03.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19-25 March 2023 and includes updates on Marburg virus disease, iatrogenic botulism, COVID-19, Influenza, Group A streptococcal infection, cholera, poliomyelitis, measles, and extensively drug-resistant Pseudomonas aeruginosa.
Læs mere
7
PRO/EDR> Pseudomonas aeruginosa - USA (04): India-made/XDR/contam. eye drops, more cases
ProMED, 18.03.2023
Tilføjet 18.03.2023
P. aeruginosa -- United States'As of 14 Mar 2023, CDC, in partnership with state and local health departments, identified 68 patients in 16 states (CA, CO, CT, FL, IL, NC, NJ, NM, NY, NV, PA, SD, TX, UT, WA, WI) with VIM-GES-CRPA, a rare strain of extensively drug-resistant _P. aeruginosa_. Thirty-seven patients were linked to 4 healthcare facility clusters. One person has died and there have been 8 reports of vision loss and 4 reports of enucleation (surgical removal of eyeball). Dates of specimen collection were from May
Læs mere
8
PRO/EDR> Pseudomonas aeruginosa - USA (03): India made, contaminated eye drops, recall
ProMED, 8.02.2023
Tilføjet 8.02.2023
P. aeruginosa -- United StatesThe Food and Drug Administration (FDA) has warned against using 'Artificial Tears' eye drops produced by a Tamil Nadu-based firm after an outbreak of drug-resistant infections was linked to the drug in the USA. This is the 3rd such controversy involving an Indian pharma company.Another controversy has hit India's pharmaceutical industry as the United States warned that an eye drop manufactured by a Tamil Nadu-based firm has caused an outbreak of the drug-resistant bacterium _Pseudomonas
Læs mere
9
PRO/EDR> Pseudomonas aeruginosa - USA (02): contaminated eye drops, XDR, CDC, recall
ProMED, 4.02.2023
Tilføjet 4.02.2023
P. aeruginosa -- United StatesPatients should stop using EzriCare Artificial Tears pending additional information and guidance from CDC and FDA. If patients were advised to use EzriCare Artificial Tears by their healthcare provider, they should follow up with their healthcare provider for recommendations about alternative treatment options. Patients who have used EzriCare preservative-free artificial tears and who have signs or symptoms of an eye infection should seek medical care immediately. At this time, there is no
Læs mere
10
PRO/EDR> Pseudomonas aeruginosa - USA: contaminated eye drops susp, fatal
ProMED, 2.02.2023
Tilføjet 2.02.2023
P. aeruginosa -- United StatesOne person has died and at least 3 others are left with permanent vision loss because of a bacterial infection possibly linked to a brand of over-the-counter eyedrops, according to the Centers for Disease Control and Prevention (CDC). A majority of those affected reported using preservative-free EzriCare Artificial Tears before becoming ill, CDC reported in a statement dated 20 Jan 2023. While the infections have not been definitively traced to the eyedrops, CDC recommended that 'patients
Læs mere
11
Early deaths associated with community-acquired and healthcare-associated bloodstream infections: a population-based study, Finland, 2004 to 2018
Keiju SK Kontula, Kirsi Skogberg, Jukka Ollgren, Asko Järvinen and Outi Lyytikäinen
Eurosurveillance latest updates, 8.09.2022
Tilføjet 9.09.2022
Background
Bloodstream infections (BSI) cause substantial morbidity and mortality.
Aim
We explored the role of causative pathogens and patient characteristics on the outcome of community-acquired (CA) and healthcare-associated (HA) BSI, with particular interest in early death.
Methods
We used national register data to identify all BSI in Finland during 2004–18. We determined the origin of BSI, patients´ underlying comorbidities and deaths within 2 or 30 days from specimen collection. A time-dependent Cox model was applied to evaluate the impact of patient characteristics and causative pathogens on the hazard for death at different time points.
Results
A total of 173,715 BSI were identified; 22,474 (12.9%) were fatal within 30 days and, of these, 6,392 (28.4%) occurred within 2 days (7.9 deaths/100,000 population). The 2-day case fatality rate of HA-BSI was higher than that of CA-BSI (5.4% vs 3.0%). Patients who died within 2 days were older than those alive on day 3 (76 vs 70 years) and had more severe comorbidities. Compared with other BSI, infections leading to death within 2 days were more often polymicrobial (11.8% vs 6.3%) and caused by Pseudomonas aeruginosa (6.2% vs 2.0%), fungi (2.9% vs 1.4%) and multidrug-resistant (MDR) pathogens (2.2% vs 1.8%), which were also predictors of death within 2 days in the model.
Conclusions
Overrepresentation of polymicrobial, fungal, P. aeruginosa and MDR aetiology among BSI leading to early death is challenging concerning the initial antimicrobial treatment. Our findings highlight the need for active prevention and prompt recognition of BSI and appropriate antimicrobial treatment.
Læs mere
12
PRO/EDR> Pseudomonas aeruginosa - Norway (02): nosocomial, fatal, contaminated washcloths
ProMED, 8.05.2022
Tilføjet 9.05.2022
Hospital-Related Infection -- Norway
Læs mere